Fatigue after initiating rivaroxaban for venous thromboembolism

BACKGROUND: Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaban has be...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Res Pract Thromb Haemost
Asıl Yazarlar: Karlsvik, Tina Margrethe, Borgenvik, Thore Langfeldt, Aadalen, Mirjam, Utne, Kristin, Førsund, Eli, Jørgensen, Camilla Tøvik, Holst, René, Jelsness‐Jørgensen, Lars‐Petter, Ghanima, Waleed
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Original Article: Thrombosis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292653/
https://ncbi.nlm.nih.gov/pubmed/32548556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12312
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller